• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Sun Wenhua

    3/18/26 4:10:21 PM ET
    $ZYBT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZYBT alert in real time by email
    SEC FORM 3SEC Form 3
    FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0104
    Estimated average burden
    hours per response:0.5
    1. Name and Address of Reporting Person*
    Sun Wenhua

    (Last)(First)(Middle)
    NO.1 LIANMENG ROAD

    (Street)
    JILIN CITY, JILIN PROVINCE132101

    (City)(State)(Zip)

    CHINA

    (Country)
    2. Date of Event Requiring Statement (Month/Day/Year)
    03/18/2026
    3. Issuer Name and Ticker or Trading Symbol
    Zhengye Biotechnology Holding Ltd [ ZYBT ]
    3a. Foreign Trading Symbol
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    Officer (give title below)Other (specify below)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date ExercisableExpiration DateTitleAmount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ Wenhua Sun03/18/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 3: SEC 1473 (03-26)
    Get the next $ZYBT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZYBT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ZYBT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Lian Wei

    3 - Zhengye Biotechnology Holding Ltd (0001975641) (Issuer)

    3/18/26 4:10:20 PM ET
    $ZYBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Liu Zhongyao

    3 - Zhengye Biotechnology Holding Ltd (0001975641) (Issuer)

    3/18/26 4:10:24 PM ET
    $ZYBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Sun Wenhua

    3 - Zhengye Biotechnology Holding Ltd (0001975641) (Issuer)

    3/18/26 4:10:21 PM ET
    $ZYBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYBT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zhengye Biotechnology Holding Limited Issues 2026 Chairman's Letter to Shareholders

    Jilin, China, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today announced that Mr. Zhenfa Han, Chairman of the Board of Directors of Zhengye, has issued a letter to shareholders. In the letter, Mr. Han highlights the Company's research and operational milestones achieved in 2025 and outlines Zhengye's strategic priorities for growth in 2026. The full text of the letter follows. Dear Shareholders, As we enter 2026, on behalf of the management of Zhengye

    2/10/26 8:30:00 AM ET
    $ZYBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial Results

    JILIN, China, July 3, 2025 /PRNewswire/ -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today announced its financial results for the fiscal year ended December 31, 2024. Mr. Songlin Song, co-chief executive officer of Zhengye, remarked, "Fiscal year 2024 was a transformational year for us, marked by strategic decisions and tough yet necessary shifts, as we navigated significant market adjustments and proactively diversified our customer base in pursuit of long-term growth. Amid global un

    7/3/25 8:30:00 AM ET
    $ZYBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zhengye Biotechnology Holding Limited Receives NASDAQ Notice Related to Late Filing of Form 20-F

    Jilin, China, May 23, 2025 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today announced that it has received a letter from the NASDAQ Stock Market, dated May 20, 2025 (the "Delinquency Letter"), notifying the Company that it is not in compliance with the requirements for continued listing set forth in NASDAQ Listing Rule 5250(c)(1) because it did not timely file its annual report on Form 20-F for the fiscal year ended December 31, 2024 (the "2024 Annual Report"). In a

    5/23/25 4:05:00 PM ET
    $ZYBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYBT
    SEC Filings

    View All

    SEC Form 6-K filed by Zhengye Biotechnology Holding Limited

    6-K - Zhengye Biotechnology Holding Ltd (0001975641) (Filer)

    2/23/26 4:10:28 PM ET
    $ZYBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Zhengye Biotechnology Holding Limited

    6-K - Zhengye Biotechnology Holding Ltd (0001975641) (Filer)

    12/12/25 4:10:35 PM ET
    $ZYBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 20-F filed by Zhengye Biotechnology Holding Limited

    20-F - Zhengye Biotechnology Holding Ltd (0001975641) (Filer)

    7/3/25 6:30:38 AM ET
    $ZYBT
    Biotechnology: Pharmaceutical Preparations
    Health Care